The Home Oxygen Therapy Apparatus segmentation by application reflects the clinical drivers that shape demand across patient groups. Chronic Obstructive Pulmonary Disease (COPD) remains the dominant segment, accounting for roughly 45 % of market volume, as long‑term oxygen supplementation is a standard of care for advanced stages. Interstitial lung disease (ILD) follows with an estimated 20 % share, driven by progressive fibrosis that necessitates continuous oxygen flow. Sleep‑related breathing disorders, chiefly obstructive sleep apnea requiring nocturnal oxygen, represent about 15 % of the market, supported by increasing diagnostic rates. Post‑operative and acute care patients contribute near 10 %, where short‑term home oxygen facilitates recovery after discharge. The residual 10 % classified as others includes rare conditions such as pulmonary hypertension and congenital heart disease, each adding niche demand. Collectively, these application categories determine product mix, pricing pressure, and geographic penetration, making them essential for forecasting total market size.